当前位置: 首页 > 期刊 > 《中外医疗》 > 2014年第11期
编号:13131844
MicroRNA—218miR—218在肾透明细胞癌中的表达及临床意义(3)
http://www.100md.com 2014年4月15日 任小强 张建国 辛士永 程涛
第1页

    参见附件。

     [3] 杨卫东,王欢,汪静.miRNAs: 肿瘤诊断治疗的潜在新型靶分子[J].现代肿瘤医学,2013,21(8):1873-1879.

    [4] 黄晓明,陈翔,贾振宇.人工microRNAs在肿瘤基因治疗中的研究[J].中国细胞生物学学报,2013,35(7):1018-1026.

    [5] Guan H, Wei G, Wu J, et al. Down-regulation of miR-218–2 and its host gene SLIT3 cooperate to promote invasion and progression of thyroid cancer[J].Journal of Clinical Endocrinology & Metabolism, 2013,89(5):2346-2352.

    [6] Davis BN, Hata A microRNA in cancer—the involvement of aberrant microRNA biogenesis regulatory pathways[J].Genes Cancer,2010(11):1100-1114.

    [7] Hassan MQ, Maeda Y, Taipaleenmaki H, et al. miR-218 Directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells[J].Journal of Biological Chemistry,2012,287(50):84-92.

    [8] Gien LT, Beauchemin MC, Thomas G. Adenocarcinoma: a unique cervical cancer[J].Gynecol Oncol,2010,116:140-146

    [9] Li Q, Zhu F, Chen P. miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer[J].Biochemical and Biophysical Research Communications,2012, 424(1):28-33.

    (收稿日期:2014-01-05)

您现在查看是摘要介绍页,详见PDF附件